甲状腺乳头状癌及滤泡状癌Ⅰ型转化生长因子β受体与增值细胞核抗原的表达状态及意义

摘要

目的观察高分化甲状腺癌Ⅰ型转化生长因子β(Transformxing Growth Factor-β),TGF-β受体与增值细胞核抗原(proliferating cell nuclear antigen,PCNA)的表达状态,讨论TGF-β抵抗机制在甲状腺乳头状癌及滤泡状癌中的可能途径.方法取25例甲状腺乳头状癌、7例甲状腺滤泡状癌及19例正常甲状腺组织标本,免疫组化检测Ⅰ型TGF-β受体和PCNA蛋白的表达水平.结果Ⅰ型TGF-β受体与PCNA在甲状腺癌中的阳性率显著高于正常甲状腺组织(P＜0.05),两者在甲状腺癌呈正相关关系(r=0.3637、P=0.0437).结论TGF-β抵抗机制在本组甲状腺癌中的实现并非通过Ⅰ型TGF-β受体的丢失,而更可能是Ⅱ型TGF-β受体丢失或TGF-β合成水平降低所至.%Objective: The expressions of type Ⅰ receptor of transforming growth factor-β (TGF-β) and proliferating cell nuclear antigen (PCNA) in the TGF-β inhibitory mechanism were investigated in thyroid carcinomas. Methods: Immunohistochemical methods were applied to measure the expressions of PCNA and type Ⅰ receptor of TGF-β in 32 specimens of thyroid carcinomas and 19 specimens of normal thyroid tissue.Results: The positive rates of PCNA and type Ⅰ receptor of TGF-β in thyroid carcinomas were significantly higher than those in normal thyroid tissue (P ＜0.05). There was a positive correlation between these two factors in thyroid carcinomas (r ＝0.3637, P=0.0437). Conclusion: The TGF-β inhibitory mechanism in thyroid carcinomas unlikely results from the low-level expression of type Ⅰ receptor of TGF-β, but the low-level expression of the type Ⅱ receptor of TGF-β or TGF-β itself.